Abstract
The effect of immunotherapy using sizofiran (SPG) on the prognosis of patients with ovarian cancers was prospectively studied in a total of 68 patients, who were randomly assigned to either a cisplatin, adriamycin and cyclophosphamide (PAC) therapy group or a PAC plus SPG combination therapy group.
The survival rate was significantly higher in patients with stage Ic, II or III cancers treated with the PAC plus SPG combination, compared with the patients treated with PAC alone. In the SPG-receiving patients with stage Ic or more advanced cancers who were treated with four cycles or more of PAC, the outcome was improved (Cox-Mantel, p=0.074; generalized Kruskal-Wallis, p=0.032). Similar improvement was also observed in the patients with non-serous adenocarcinomas (Cox-Mantel, p-0.076; generalized Krukal-Wallis, p=0.045). No side effects attributable to SPG were recorded.
The present results suggest that the use of SPG in combination with long-term chemotherapy improves the postoperative prognosis in ovarian cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- SPG:
-
sizofiran
References
Hainsworth, J.D., Grosh, W.W., Burnett, L.S., Jones, H.W., Wolff, S.N. and Greco, F.A. Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Int Med 1988; 108: 165–170.
Luesley, D., Lawton, F., Blackledge, G., Hilton, C., Kelly, K., Rollason, T., Wade-Evans, T., Jordan, J., Fielding, J. and Latief, T. Failure of second-look laparotomy to influence Survival in epithelial ovarian cancer. Lancet 1988; ii: 599–603.
Bertelsen, K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990; 38: 203–209.
Howell, S.B., Zimm, S., Markman, M., Abramson, I.S., Cleary, S., Lucas, W.E., and Weiss, R.J. Long term survival of advanced refractory ovarian carcinoma patient with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607–1612.
Dottino, P.R., Goodman, H.M., Kredentser, D., Rosenberg, M., and Cohen, C.J. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma. Gynecol Oncol 1987; 27: 350–356.
Okamura, K., Suzuki, M., Chihara, T., Fujiwara, A., Fukuda, T., Goto, S., Ichinohe, K., Jimi, S., Kasamatsu, T., Kawai, N., Mizuguchi, K., Mori, S., Nakano, H., Noda, K., Sekiba, K., Suzuki, K., Suzuki, T., Takahashi, K., Takeuchi, K., Takeuchi, S., Yajima, A. and Ogawa, N. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study. Cancer 1986; 58: 865–872.
Norisuye, K., Yanai, T. and Fujita, H. Triple helix of a schizophyllum commune polysaccharide in aqueous solution. J Polymer Sci 1980; 18: 547–558.
Yoneda, K., Ueta, E., Yamamoto, T. and Osaki, T. Immunoregularoty effects of sizofiran (SPG) on lymphocytes and polymorphonuclear leukocytes. Clin Exp Immunol 1991; 86: 229–235.
Tsuchiya, Y, Matsutani, M., Inoue, M., Sato, S., Asano, T. and Yajima, M. Effect of a glucan, sizofiran, on natural-killer activity of 5-fluorouracil-treated murine bone marrow cells. Cancer Immunol Immunother 1991; 34: 17–23.
Ogawa, Y., Goodman, G.B., Chaplin, D.J., Grulkey, W. and Lam, G.K.Y. Combination therapy of pions and SPG (sonifian, schizophylian), a biological response modifier for mouse tumor systems. Int J Radiation Oncol Biol Phys 1990; 18: 1415–1420.
Ehrlich, C.E., Einhorn, L., Williams, S.D. and Morgan, J. Chemotherapy for stage III–IV epithelial ovarian cancer with cis-dichlorodiamineplatinum (II), adriamycin, and cyclophosphamide: A preliminary report. Cancer Treat Rep. 1979: 63; 281–288.
Podczaski, E., Manetta, A., Kaminski, P., Ricelli, A., Larson, J., Degeest, K. and Mortel, R. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol 1990; 36: 43–47.
Inoue, M., Nakanishi, K., Ueda, G. and Tanizawa, O. Intermittent intensive combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide cyclic PAC chemotherapy for the ovarian cancer. Am J Clinicol Oncol 1992; 15: 1–6.
Bradley, G., Juranka, PF. and Ling, V. Mechanism of multidrug resistance. Biochem Biophys Acta 1988; 948: 87–128.
Neijh, JP. Complete remission at laparotomy: Still a gold standard in Ovarian Cancer? Lancet 1986; ii: 1028.
Fujimoto, S., Furue, H., Kimura, T., Kondo, T., Orita, K., Taguchi, T., Yoshida, K., and Ogawa, N. Clinical outcome of postooperative adjuvant immunochemotherapy with Sizofiram for patients with resectable gastric cancer: A randomised controlled study. Eur J Cancer 1991; 27: 114–118.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inoue, M., Tanaka, Y., Sugita, N. et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy 6, 13–18 (1993). https://doi.org/10.1007/BF01877381
Issue Date:
DOI: https://doi.org/10.1007/BF01877381